Overview
Title
To amend the Public Health Service Act to reauthorize the BOLD Infrastructure for Alzheimer’s Act, and for other purposes.
ELI5 AI
The bill wants to keep helping people understand and research Alzheimer's disease by giving $33 million every year for five years, but it doesn't clearly say how exactly the money will be used or checked.
Summary AI
The bill, S. 3775, seeks to amend the Public Health Service Act by reauthorizing programs related to the BOLD Infrastructure for Alzheimer's Act. It proposes updates to the coordination of activities led by the Centers for Disease Control and Prevention and other agencies in promoting public health knowledge about Alzheimer's disease. Additionally, the bill provides for continued funding for these programs, allocating $33 million annually from 2025 to 2029 to support Alzheimer's research and public health initiatives.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
The proposed legislation, known as S. 3775, aims to amend the Public Health Service Act with the primary goal of reauthorizing the Building Our Largest Dementia Infrastructure for Alzheimer's (BOLD) Act. By doing so, it continues efforts to support programs related to Alzheimer's disease and other related dementias. This initiative is a reflection of the ongoing need to address these conditions through coordinated public health approaches, enhanced awareness, and community-level action.
General Summary
The bill's short title is the "BOLD Infrastructure for Alzheimer's Reauthorization Act of 2024," which indicates its focus on expanding and reauthorizing previous legislation surrounding Alzheimer's disease. The bill seeks to enhance existing programs by improving collaboration with the Centers for Disease Control and Prevention (CDC) and other agencies. Additionally, it emphasizes promoting public health awareness and converting research findings into practical, community-level practices. A notable aspect of the legislation is its proposal to allocate $33 million annually from 2025 through 2029 to support these efforts.
Significant Issues
There are several noteworthy issues regarding the bill's provisions. Firstly, the allocation of $33 million per year lacks specific details about how these funds will be used. Without a clear justification or breakdown, there may be concerns over financial accountability and the potential for waste.
Another issue is the vague language in the amendments concerning coordination roles among various agencies. This lack of specificity might lead to unclear responsibilities and accountability, potentially affecting the effectiveness of the Alzheimer's programs funded under this act.
Additionally, the bill's short title, while concise, does not offer the public immediate insight into the act's contents or implications, leaving some uncertainty about what this reauthorization aims to accomplish.
Impact on the Public
Broadly, the bill's impact on the public hinges on its ability to improve Alzheimer's-related programs and awareness. By reauthorizing and funding these initiatives, there is potential for enhanced support and resources for individuals and families affected by Alzheimer's disease. Public health campaigns and efforts to translate research into practice could increase knowledge and preventive measures among communities.
However, the lack of clarity on the use of allocated funds and the roles of coordinating agencies may impact the efficiency and accountability of these programs. If not addressed, these issues could undermine public trust and the perceived effectiveness of government action against Alzheimer's disease.
Impact on Stakeholders
Specific stakeholders such as state health departments, public health agencies, and Alzheimer's research organizations may find this bill beneficial. The proposed funding, if properly allocated, could provide them with additional resources to implement and expand their programs.
Conversely, if the concerns regarding financial accountability and vague coordination roles are not rectified, stakeholders may face challenges in executing their responsibilities effectively. Additionally, individuals and families directly impacted by Alzheimer's might find programs lacking if these systemic issues are not resolved.
In conclusion, while the bill represents a positive step towards addressing Alzheimer's disease through reauthorization, addressing the identified issues will be crucial to ensure its effectiveness and transparency. Promoting clear allocation of resources and defined roles could enhance its positive impact on both the general public and specific stakeholders involved.
Financial Assessment
The bill, labeled S. 3775, proposes the continuation and amendment of provisions under the Public Health Service Act, specifically reauthorizing programs related to Alzheimer's disease. This reauthorization includes financial allocations that merit further examination, especially concerning their transparency and utilization.
Financial Summary
The primary financial element of the bill is the allocation of $33 million annually from fiscal years 2025 through 2029. These funds are designated to support Alzheimer's research and public health initiatives. Such an allocation underscores the ongoing federal commitment to addressing Alzheimer's disease and related dementias through research, infrastructure improvements, and public awareness programs.
Financial Issues
The bill's financial arrangements link to specific issues, primarily concerning transparency and specificity:
Lack of Detailed Justification: The bill earmarks $33 million each year but does not provide detailed justification or contextual rationale for this specific amount. This lack of clarity may lead to concern regarding financial accountability and the potential for inefficiencies or waste. Without clear directives or plans for how the funds should be used, stakeholders might question the allocation's adequacy or overextension.
Lack of Transparency and Financial Oversight: While the allocation of resources is crucial, the bill does not specify the methods or mechanisms for financial auditing or detailed budget breakdowns for the spending. Such omissions could raise concerns about transparency and proper oversight. Without a clear framework for how the money will be monitored and assessed, there is a risk that funds could be mismanaged.
Coordination and Responsibility Concerns
In the context of financial allocation, the framework for coordination among agencies, especially the Centers for Disease Control and Prevention (CDC) and other involved bodies, is somewhat vague. This vagueness could pose challenges in ensuring that the allocated funds are effectively utilized and that duplication of efforts is minimized. Clear roles and responsibilities need to be established to enhance the program's effectiveness and prevent any misuse of the provided funds.
By addressing these financial transparency and accountability issues, the bill could better secure confidence in how the allocated funds will drive meaningful advances in Alzheimer's research and public health initiatives. As legislation progresses, stakeholders might advocate for more explicit financial guidelines to ensure optimal usage of taxpayer money.
Issues
The allocation of $33,000,000 for each of fiscal years 2025 through 2029 lacks specific justification or clarity regarding the use of these funds, which could lead to concerns about financial accountability and waste. (Section 2)
The language specifying coordination roles in the amendments might be too vague, potentially resulting in unclear responsibilities and accountability for each agency involved in Alzheimer's programs. This could affect program effectiveness. (Section 2)
The short title 'BOLD Infrastructure for Alzheimer's Reauthorization Act of 2024' is very brief and does not shed light on the contents or implications of the act, leaving the public uninformed about what the act entails. (Section 1)
There is no detailed information on spending, specific allocations, or any financial auditing provisions provided in the bill, which could raise transparency and oversight concerns. (Section 1)
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The section provides the official short title of the Act, which is the “Building Our Largest Dementia Infrastructure for Alzheimer's Reauthorization Act of 2024” or simply the “BOLD Infrastructure for Alzheimer's Reauthorization Act of 2024”.
2. Extension of programs with respect to Alzheimer's disease and related dementias Read Opens in new tab
Summary AI
The proposed amendments to the Public Health Service Act aim to enhance programs for Alzheimer's disease and related dementias by improving coordination with the CDC, promoting public health awareness, and translating research findings into community practices. It also suggests funding of $33 million annually for these programs from 2025 through 2029.
Money References
- (a) Cooperative agreements to States and public health departments for Alzheimer’s disease and related dementias.—Section 398 of the Public Health Service Act (42 U.S.C. 280c–3) is amended— (1) in subsection (a)— (A) in the matter preceding paragraph (1), by striking “in coordination with the Director of the Centers for Disease Control and Prevention and” and inserting “acting through the Director of the Centers for Disease Control and Prevention, and in coordination with”; and (B) in paragraph (7), by adding a period at the end; and (2) by transferring subsection (f) to appear after subsection (e). (b) Promotion of public health knowledge and awareness of Alzheimer’s disease and related dementias.—Section 398A(a) of the Public Health Service Act (42 U.S.C. 280c–4(a)) is amended— (1) in paragraph (1), in the matter preceding subparagraph (A), by striking “in coordination with the Director of the Centers for Disease Control and Prevention and the heads of other agencies as” and inserting “acting through the Director of the Centers for Disease Control and Prevention, and in coordination with the heads of other agencies, as”; and (2) in paragraph (2)(C)— (A) in clause (vii), by striking “; and” and inserting a semicolon; (B) by redesignating clause (viii) as clause (ix); and (C) by inserting after clause (vii) the following: “(viii) identifying and translating findings from clinical trials and other studies on Alzheimer's disease and related dementias, including studies on risk reduction, for application and integration into effective and sustained community-level evidence-based practices, interventions, and policies; and”. (c) Reauthorization of programs.—Section 398B(e) of the Public Health Service Act (42 U.S.C. 280c–5(e)) is amended by inserting “, and $33,000,000 for each of fiscal years 2025 through 2029” before the period at the end. ---